Full Breakdown
TrumpRx Expands Discount Drug Offerings with Abbvie and Genentech
4/7/2026, 3:03:21 AM
Expansion of Discounted Medications
American pharmaceutical companies Abbvie and Genentech are set to begin selling popular medications on the White House's discounted pharmaceutical site, known as "TrumpRx," starting Monday. This expansion marks the addition of the 10th and 11th companies to the platform, which aims to provide reduced prices for certain prescription drugs. Abbvie will offer its medication Humira, used for treating rheumatoid arthritis, Crohn's disease, and ulcerative colitis, at an 86% discount, bringing the price down from over $6,900 to approximately $950 for uninsured patients. Genentech will sell Xofluza, a flu treatment, for around $50, reduced from $168.
Background on TrumpRx
The Trump administration has been actively working to lower prescription drug prices through initiatives like "most-favored-nation" agreements. These agreements require pharmaceutical companies to sell medications to uninsured U.S. consumers at prices comparable to those available in other countries. Since its launch in February, TrumpRx has expanded its offerings from about 40 drugs to over 61, with additional companies like Amgen also joining the initiative to provide discounted medications.
Official Statements & Responses
A White House official confirmed the new agreements with Abbvie and Genentech, stating that the administration is also working to ensure that individuals on government insurance can utilize copays for the drugs available on TrumpRx. However, the proposed "Great Healthcare Plan," which aims to codify these discount prescription deals, has yet to be taken up by Congress.
Criticism & Opposition
Critics argue that the discounts offered through TrumpRx primarily benefit uninsured individuals, as those with insurance typically pay lower prices already. This raises concerns about the accessibility of affordable medications for all patients, regardless of their insurance status. Additionally, some stakeholders question the long-term sustainability of these discount agreements and their potential impact on the pharmaceutical market.
Conflicting Reports & Gaps
While the White House has announced significant discounts for specific medications, there is limited information on how these changes will affect overall drug pricing trends in the U.S. Furthermore, the lack of Congressional action on the proposed healthcare plan raises questions about the future of the TrumpRx initiative.
Verbatim Quotes
“TrumpRx will feature coupons for Humira that will drop the price to $950, according to a White House official.” — White House Official
“Prices for the Humira Pen, also called adalimumab, can cost over $6,900 for uninsured individuals.” — CBS News Report
“That prescription will cost around $50, negotiated down from $168, according to a White House official.” — White House Official
This expansion of TrumpRx reflects ongoing efforts by the Trump administration to address prescription drug affordability, though it remains to be seen how effective these measures will be in the long term.
